董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Donald Williams | 男 | Director | 58 | 17.00万美元 | 未持股 | 2017-04-19 |
| Jeffrey P. Rydin | 男 | Director | 50 | 未披露 | 未持股 | 2017-04-19 |
| Mortimer Berkowitz III | 男 | Chairman of the Board of Directors | 63 | 未披露 | 未持股 | 2017-04-19 |
| R. Ian Molson | 男 | Director | 62 | 13.60万美元 | 未持股 | 2017-04-19 |
| Stephen E. O'Neil | 男 | Director | 84 | 12.68万美元 | 未持股 | 2017-04-19 |
| David H. Mowry | 男 | Director | 54 | 未披露 | 未持股 | 2017-04-19 |
| Terry M. Rich | 男 | Director and Chief Executive Officer | 49 | 154.59万美元 | 未持股 | 2017-04-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan Allen | 男 | Executive Vice President, Commercial Operations | 57 | 未披露 | 未持股 | 2017-04-19 |
| Brian R. Snider | 男 | Executive Vice President, Strategic Marketing and Product Development | 39 | 未披露 | 未持股 | 2017-04-19 |
| Jeffrey G. Black | 男 | Executive Vice President and Chief Financial Officer | 48 | 未披露 | 未持股 | 2017-04-19 |
| Craig E. Hunsaker | 男 | Executive Vice President, People & Culture and General Counsel | 53 | 未披露 | 未持股 | 2017-04-19 |
| Terry M. Rich | 男 | Director and Chief Executive Officer | 49 | 154.59万美元 | 未持股 | 2017-04-19 |
| Michael Plunkett | 男 | President and Chief Operating Officer | 59 | 97.71万美元 | 未持股 | 2017-04-19 |
董事简历
中英对照 | 中文 | 英文- Donald Williams
-
Donald Williams，自2021年4月起担任董事会成员，并于2024年2月成为董事会主席。此前，Williams先生自2019年5月起担任伦敦商学院董事会成员。他还担任Akari Therapeutics PLC的董事会成员（2016年至2024年），Forte Biosciences, Inc.的董事会成员（2020年至2024年），以及ImpediMed， Inc.的董事会成员（2017年至2023年）。从2014年到2019年，他是阿戴拉治疗公司的董事会成员。从2015年到2021年，他担任Alphatec Spine， Inc.的董事会成员。从2007年到2014年，他是Grant Thornton LLP的合伙人和国家生命科学负责人，并在Ernst & Young LLP担任合伙人20多年。2001年至2014年，他担任the San Diego Venture Group的董事会成员，在此期间，他还担任该集团的总裁兼董事长。他也是南加州Young vc的创始成员。他持有Southern Illinois大学的会计学士学位，并完成了California大学， Los Angeles Anderson School of Business的董事教育和认证课程。
Donald Williams has served as a member of Board since April 2021 and became chairman of Board in February 2024. Previoly, Mr. Williams served on the LBS board of directors since May 2019. Mr. Williams has also served as a member of the board of directors of Akari Therapeutics PLC from 2016 until 2024, a member of the board of directors of Forte Biosciences, Inc. from 2020 until 2024, and a member of the board of directors of ImpediMed, Inc. from 2017 until 2023. From 2014 to 2019, Mr. Williams was a member of the board of directors of Adhera Therapeutics, Inc. From 2015 to 2021, Mr. Williams served as a member of the board of directors of Alphatec Spine, Inc. From 2007 to 2014, Mr. Williams was a Partner and the National Life Sciences Leader for Grant Thornton LLP, and spent over 20 years as a partner at Ernst & Young LLP. From 2001 to 2014, Mr. Williams served on the board of directors of the San Diego Venture Group, during which time he also served as the group's president and chairman. Mr. Williams was also a founding member of the Young VCs of Southern California. Mr. Williams received a B.A. in accountancy from Southern Illinois University and completed the director education and certification program at the University of California, Los Angeles Anderson School of Biness. - Donald Williams，自2021年4月起担任董事会成员，并于2024年2月成为董事会主席。此前，Williams先生自2019年5月起担任伦敦商学院董事会成员。他还担任Akari Therapeutics PLC的董事会成员（2016年至2024年），Forte Biosciences, Inc.的董事会成员（2020年至2024年），以及ImpediMed， Inc.的董事会成员（2017年至2023年）。从2014年到2019年，他是阿戴拉治疗公司的董事会成员。从2015年到2021年，他担任Alphatec Spine， Inc.的董事会成员。从2007年到2014年，他是Grant Thornton LLP的合伙人和国家生命科学负责人，并在Ernst & Young LLP担任合伙人20多年。2001年至2014年，他担任the San Diego Venture Group的董事会成员，在此期间，他还担任该集团的总裁兼董事长。他也是南加州Young vc的创始成员。他持有Southern Illinois大学的会计学士学位，并完成了California大学， Los Angeles Anderson School of Business的董事教育和认证课程。
- Donald Williams has served as a member of Board since April 2021 and became chairman of Board in February 2024. Previoly, Mr. Williams served on the LBS board of directors since May 2019. Mr. Williams has also served as a member of the board of directors of Akari Therapeutics PLC from 2016 until 2024, a member of the board of directors of Forte Biosciences, Inc. from 2020 until 2024, and a member of the board of directors of ImpediMed, Inc. from 2017 until 2023. From 2014 to 2019, Mr. Williams was a member of the board of directors of Adhera Therapeutics, Inc. From 2015 to 2021, Mr. Williams served as a member of the board of directors of Alphatec Spine, Inc. From 2007 to 2014, Mr. Williams was a Partner and the National Life Sciences Leader for Grant Thornton LLP, and spent over 20 years as a partner at Ernst & Young LLP. From 2001 to 2014, Mr. Williams served on the board of directors of the San Diego Venture Group, during which time he also served as the group's president and chairman. Mr. Williams was also a founding member of the Young VCs of Southern California. Mr. Williams received a B.A. in accountancy from Southern Illinois University and completed the director education and certification program at the University of California, Los Angeles Anderson School of Biness.
- Jeffrey P. Rydin
-
Jeffrey P. Rydin从2011年10月担任我司的全球销售部的总裁。在这之前，他从2010年1月到2011年11月担任我司的美洲销售部的执行副总裁，从2005年12月到2009年12月担任我司的美国销售部高级副总裁。加入我司前，Rydin先生从2003年1月到2005年12月担任假体生物骨材脊柱股份有限公司（Orthobiologics for DePuy Spine, Inc.）的区域副总裁，该公司是强生假体公司（Johnson & Johnson “DePuy”）的子公司。Rydin先生在医疗保健行业拥有接近20年的销售经验，他还担任Orquest股份有限公司（Orquest, Inc.）的销售部副总裁，该公司为矫形手术和脊柱外科手术开发基于生物学的移植物，该公司被强生假体公司收购。他也担任Symphonix设备股份有限公司（Symphonix Devices, Inc.）的销售部总监，该公司是一家听力技术公司，他还担任综合外科创新股份有限公司（General Surgical Innovations, Inc.）销售部的总监，该公司开发并生产用于微创外科手术的组织解剖系统，该公司被泰科国际有限责任公司（ Tyco International Ltd）收购。Rydin先生在加利福尼亚州尔湾大学获得社会生态学的文学学士学位。
Jeffrey P. Rydin has served as a Special Advisor to the Board of Directors since September 2016 and has spent more than 27 years in the medical device and healthcare industries. Prior to joining Alphatec as Special Advisor to the Board, Mr. Rydin served as Chief Sales Officer of Ellipse Technologies, Inc., a medical technology company, from September 2015 until its purchase by NuVasive, Inc. in February 2016. Before joining Ellipse, Mr. Rydin served as President of Global Sales at NuVasive October 2011 to March 2013 where he was responsible for NuVasive’s worldwide sales efforts, including the oversight of strategic sales development, sales administration, divisional sales directors and sales training. Prior to his position of President of Global Sales, he served as Executive Vice President of Sales-Americas and Senior Vice President, U.S. Sales since joining NuVasive in December 2005. Prior to joining NuVasive, Mr. Rydin served as Area Vice President, Sales (US Southeast region) at DePuy Spine, Inc. from January 2003 to December 2005. Mr. Rydin also served as Vice President of Sales at Orquest, Inc. from December 2001 to January 2003 Director of Sales at Symphonix Devices, Inc. from April 2000 to December 2001 and Director of Sales at General Surgical Innovations, Inc. from October 1996 to March 2000. Mr. Rydin also has served in various executive and leadership sales roles at General Surgical Innovations, Baxter Healthcare, US Surgical Corporation and Xerox. He currently serves as director of Minimally Invasive Devices, LLC, which develops laparoscopic visualization systems. Mr. Rydin received a B.A. degree in Social Ecology from the University of California, Irvine. - Jeffrey P. Rydin从2011年10月担任我司的全球销售部的总裁。在这之前，他从2010年1月到2011年11月担任我司的美洲销售部的执行副总裁，从2005年12月到2009年12月担任我司的美国销售部高级副总裁。加入我司前，Rydin先生从2003年1月到2005年12月担任假体生物骨材脊柱股份有限公司（Orthobiologics for DePuy Spine, Inc.）的区域副总裁，该公司是强生假体公司（Johnson & Johnson “DePuy”）的子公司。Rydin先生在医疗保健行业拥有接近20年的销售经验，他还担任Orquest股份有限公司（Orquest, Inc.）的销售部副总裁，该公司为矫形手术和脊柱外科手术开发基于生物学的移植物，该公司被强生假体公司收购。他也担任Symphonix设备股份有限公司（Symphonix Devices, Inc.）的销售部总监，该公司是一家听力技术公司，他还担任综合外科创新股份有限公司（General Surgical Innovations, Inc.）销售部的总监，该公司开发并生产用于微创外科手术的组织解剖系统，该公司被泰科国际有限责任公司（ Tyco International Ltd）收购。Rydin先生在加利福尼亚州尔湾大学获得社会生态学的文学学士学位。
- Jeffrey P. Rydin has served as a Special Advisor to the Board of Directors since September 2016 and has spent more than 27 years in the medical device and healthcare industries. Prior to joining Alphatec as Special Advisor to the Board, Mr. Rydin served as Chief Sales Officer of Ellipse Technologies, Inc., a medical technology company, from September 2015 until its purchase by NuVasive, Inc. in February 2016. Before joining Ellipse, Mr. Rydin served as President of Global Sales at NuVasive October 2011 to March 2013 where he was responsible for NuVasive’s worldwide sales efforts, including the oversight of strategic sales development, sales administration, divisional sales directors and sales training. Prior to his position of President of Global Sales, he served as Executive Vice President of Sales-Americas and Senior Vice President, U.S. Sales since joining NuVasive in December 2005. Prior to joining NuVasive, Mr. Rydin served as Area Vice President, Sales (US Southeast region) at DePuy Spine, Inc. from January 2003 to December 2005. Mr. Rydin also served as Vice President of Sales at Orquest, Inc. from December 2001 to January 2003 Director of Sales at Symphonix Devices, Inc. from April 2000 to December 2001 and Director of Sales at General Surgical Innovations, Inc. from October 1996 to March 2000. Mr. Rydin also has served in various executive and leadership sales roles at General Surgical Innovations, Baxter Healthcare, US Surgical Corporation and Xerox. He currently serves as director of Minimally Invasive Devices, LLC, which develops laparoscopic visualization systems. Mr. Rydin received a B.A. degree in Social Ecology from the University of California, Irvine.
- Mortimer Berkowitz III
-
Mortimer Berkowitz III 自2005年3月以来担任董事会董事。从2007年4月至2011年7月，他曾担任我公司以及Alphatec Spine公司的董事会主席。自2011年8月，他担任董事会执行委员会主席。他是 HGP, LLC公司管理部的成员，该公司是HealthpointCapital Partners, LP公司的普通合伙人，同时他还是HealthpointCapital, LLC公司的总裁兼总经理以及董事会成员。自2002年8月HGP, LLC公司成立以来，他一直在该公司工作。自HealthpointCapital, LLC公司在2002年7月成立以来，他一直担任该公司的经理兼董事会成员，2005年2月，他担任该公司的总裁。在加入HealthpointCapital, LLC公司之前，他曾是是BPI Capital Partners, LLC公司的经理兼合作创始人，该公司是成立于1990年的私募股权投资公司。在1990年之前，他在Goldman, Sachs & Co., Lehman Brothers Incorporated and Merrill Lynch & Co投资银行工作11年。他是Blue Belt Holdings公司以及外科机器人公司的董事会主席，同时他还是BioHorizons公司的董事，该公司是私人牙移植公司。他是MicroDental 公司董事，该公司是主要牙齿技工室公司。以上公司都是HealthpointCapital公司风险投资公司。他也在哈佛大学公共健康专业的领导委员会工作。
Mortimer Berkowitz III has served as Chairman of the Board of Directors of us and Alphatec Spine, Inc., our wholly-owned subsidiary “Alphatec Spine”, since December 2016 and has been a member of the Board of Directors since March 2005. He served as Chairman of the Board of Directors from April 2007 through July 2011. Since August 2011 Mr. Berkowitz has served as the Chairman of the Executive Committee of the Board of Directors. He is President and Chief Executive Officer of InnovaHealth Partners, LP, a private equity firm he founded in January 2017. Mr. Berkowitz also is a Managing Member of HGP, LLC-the general partner of HealthpointCapital Partners, LP, a private equity firm-and President, a member of the Board of Managers and a Managing Director of HealthpointCapital, LLC. He has held the position with HGP, LLC from its formation in August 2002 the positions of Managing Director and member of the Board of Managers of HealthpointCapital, LLC from its formation in July 2002 and the position of President of HealthpointCapital, LLC beginning February 2005. From 1990 to 2002 Mr. Berkowitz was Managing Director and co-founder of BPI Capital Partners, LLC, a private equity firm. Prior to 1990 Mr. Berkowitz spent 11 years in the investment banking industry with Goldman, Sachs & Co. (1979-1982), Lehman Brothers Incorporated (1982-1987) and Merrill Lynch & Co. (1987-1990). Since 2011 he has served as Chairman of the Board of Directors of Blue Belt Holdings, Inc., a surgical robotics company, a director of BioHorizons, Inc., a dental implant company since 2006 and a director of MicroDental Inc., a leading dental laboratory company since 2006 all of which are or were (prior to acquisition) HealthpointCapital portfolio companies. He also serves on the Leadership Council of the Harvard School of Public Health. Mr. Berkowitz earned an M.B.A. degree from the Columbia Graduate School of Business and a B.A. degree from Harvard. - Mortimer Berkowitz III 自2005年3月以来担任董事会董事。从2007年4月至2011年7月，他曾担任我公司以及Alphatec Spine公司的董事会主席。自2011年8月，他担任董事会执行委员会主席。他是 HGP, LLC公司管理部的成员，该公司是HealthpointCapital Partners, LP公司的普通合伙人，同时他还是HealthpointCapital, LLC公司的总裁兼总经理以及董事会成员。自2002年8月HGP, LLC公司成立以来，他一直在该公司工作。自HealthpointCapital, LLC公司在2002年7月成立以来，他一直担任该公司的经理兼董事会成员，2005年2月，他担任该公司的总裁。在加入HealthpointCapital, LLC公司之前，他曾是是BPI Capital Partners, LLC公司的经理兼合作创始人，该公司是成立于1990年的私募股权投资公司。在1990年之前，他在Goldman, Sachs & Co., Lehman Brothers Incorporated and Merrill Lynch & Co投资银行工作11年。他是Blue Belt Holdings公司以及外科机器人公司的董事会主席，同时他还是BioHorizons公司的董事，该公司是私人牙移植公司。他是MicroDental 公司董事，该公司是主要牙齿技工室公司。以上公司都是HealthpointCapital公司风险投资公司。他也在哈佛大学公共健康专业的领导委员会工作。
- Mortimer Berkowitz III has served as Chairman of the Board of Directors of us and Alphatec Spine, Inc., our wholly-owned subsidiary “Alphatec Spine”, since December 2016 and has been a member of the Board of Directors since March 2005. He served as Chairman of the Board of Directors from April 2007 through July 2011. Since August 2011 Mr. Berkowitz has served as the Chairman of the Executive Committee of the Board of Directors. He is President and Chief Executive Officer of InnovaHealth Partners, LP, a private equity firm he founded in January 2017. Mr. Berkowitz also is a Managing Member of HGP, LLC-the general partner of HealthpointCapital Partners, LP, a private equity firm-and President, a member of the Board of Managers and a Managing Director of HealthpointCapital, LLC. He has held the position with HGP, LLC from its formation in August 2002 the positions of Managing Director and member of the Board of Managers of HealthpointCapital, LLC from its formation in July 2002 and the position of President of HealthpointCapital, LLC beginning February 2005. From 1990 to 2002 Mr. Berkowitz was Managing Director and co-founder of BPI Capital Partners, LLC, a private equity firm. Prior to 1990 Mr. Berkowitz spent 11 years in the investment banking industry with Goldman, Sachs & Co. (1979-1982), Lehman Brothers Incorporated (1982-1987) and Merrill Lynch & Co. (1987-1990). Since 2011 he has served as Chairman of the Board of Directors of Blue Belt Holdings, Inc., a surgical robotics company, a director of BioHorizons, Inc., a dental implant company since 2006 and a director of MicroDental Inc., a leading dental laboratory company since 2006 all of which are or were (prior to acquisition) HealthpointCapital portfolio companies. He also serves on the Leadership Council of the Harvard School of Public Health. Mr. Berkowitz earned an M.B.A. degree from the Columbia Graduate School of Business and a B.A. degree from Harvard.
- R. Ian Molson
-
R. Ian Molson自2005年7月开始担任Alphatec Spine公司的董事。他自2004年9月开始担任 Cayzer Continuation PCC公司经理，该公司是一家投资公司。从2004年开始，他担任 HealthpointCapital, LLC 公司的经理。从2009年12年开始，他担任Central European Petroleum的经理，并在2010年12月，他担任该公司的副主席。自2013年10月，他担任RM2公司的主席。2010年12月，他担任Royal Marsden NHS 信托基金会和 Royal Marsden 慈善医院主席。从1996年6月至2004年5月，他曾担任Molson公司董事，该公司是酿造业的领军企业，并且从1999年6月至2004年5月，他曾担任Molson公司的副董事长兼执行委员会主席。在1977年至1997年之间，他任职于Credit Suisse First Boston公司，并以各种身份受聘于该公司，其中包括运营总监的职位。自1993年至1997年，他在欧洲投资银行部担任智囊团，该职位包括公司金融，咨询，兼并以及收购业务，业务范围涵盖欧洲，俄罗斯，非洲以及中东。在过去的5年，他担任Sapphire Industrial公司的董事，这是一家特色的收购公司，并在他担任董事期间该公司上市了。现在他已经不是这家公司的董事了。
R. Ian Molson has served as a Director of us and Alphatec Spine since July 2005. Mr. Molson has served as a director of Cayzer Continuation PCC, an investment company, since September 2004. Mr. Molson has served as a director of HealthpointCapital, LLC since 2004. Mr. Molson has served as a director since December 2009 and Deputy Chairman since December 2010 of Central European Petroleum Ltd. Since October 2013 Mr. Molson has also served as Chairman of RM2. Since December 2010 Mr. Molson has also served as Chairman of the Royal Marsden NHS Foundation Trust and the Royal Marsden Hospital Charity. From 1996 until 2004 Mr. Molson served as a director of Molson, Inc., a leader in the brewing industry, and from 1999 until 2004 he also served as Deputy Chairman and Chairman of the Executive Committee at Molson, Inc. Between 1977 and 1997 he was employed by Credit Suisse First Boston in various capacities, including Managing Director. From 1993 to 1997 Mr. Molson served as Co-Head of the Investment Banking Department in Europe, a position which encompassed corporate finance, corporate advisory, mergers and acquisitions businesses in Europe, Russia, Africa and the Middle East. Mr. Molson earned a B.A. degree from Harvard. - R. Ian Molson自2005年7月开始担任Alphatec Spine公司的董事。他自2004年9月开始担任 Cayzer Continuation PCC公司经理，该公司是一家投资公司。从2004年开始，他担任 HealthpointCapital, LLC 公司的经理。从2009年12年开始，他担任Central European Petroleum的经理，并在2010年12月，他担任该公司的副主席。自2013年10月，他担任RM2公司的主席。2010年12月，他担任Royal Marsden NHS 信托基金会和 Royal Marsden 慈善医院主席。从1996年6月至2004年5月，他曾担任Molson公司董事，该公司是酿造业的领军企业，并且从1999年6月至2004年5月，他曾担任Molson公司的副董事长兼执行委员会主席。在1977年至1997年之间，他任职于Credit Suisse First Boston公司，并以各种身份受聘于该公司，其中包括运营总监的职位。自1993年至1997年，他在欧洲投资银行部担任智囊团，该职位包括公司金融，咨询，兼并以及收购业务，业务范围涵盖欧洲，俄罗斯，非洲以及中东。在过去的5年，他担任Sapphire Industrial公司的董事，这是一家特色的收购公司，并在他担任董事期间该公司上市了。现在他已经不是这家公司的董事了。
- R. Ian Molson has served as a Director of us and Alphatec Spine since July 2005. Mr. Molson has served as a director of Cayzer Continuation PCC, an investment company, since September 2004. Mr. Molson has served as a director of HealthpointCapital, LLC since 2004. Mr. Molson has served as a director since December 2009 and Deputy Chairman since December 2010 of Central European Petroleum Ltd. Since October 2013 Mr. Molson has also served as Chairman of RM2. Since December 2010 Mr. Molson has also served as Chairman of the Royal Marsden NHS Foundation Trust and the Royal Marsden Hospital Charity. From 1996 until 2004 Mr. Molson served as a director of Molson, Inc., a leader in the brewing industry, and from 1999 until 2004 he also served as Deputy Chairman and Chairman of the Executive Committee at Molson, Inc. Between 1977 and 1997 he was employed by Credit Suisse First Boston in various capacities, including Managing Director. From 1993 to 1997 Mr. Molson served as Co-Head of the Investment Banking Department in Europe, a position which encompassed corporate finance, corporate advisory, mergers and acquisitions businesses in Europe, Russia, Africa and the Middle East. Mr. Molson earned a B.A. degree from Harvard.
- Stephen E. O'Neil
-
Stephen E. O'Neil自2005年7月起担任Alphatec Holdings，Inc.和Alphatecs Spine的董事。1991年5月，他成立了O'Neil Group，主要在并购、融资和公司战略领域向客户提供法律和财务咨询。在此之前，O'Neil先生与保罗·米什金（Paul Mishkin）以米什金·奥尼尔的名义建立了法律合伙关系，以从事一般公司法和商业法。在此之前，他共同创立了两家公司，Syntro Corporation和NovaCare，Inc.，这两家公司后来成为上市公司。O'Neil先生在Cravath Swaine&Moore开始了他的法律生涯。O'Neil先生还曾在City Investing Company担任过一系列高管职位，包括总裁和副董事长。
Stephen E. O'Neil has served as a Director of Alphatec Holdings, Inc. and Alphatec Spine since July 2005. In May 1991 he founded The O'Neil Group, which provided legal and financial advice to clients primarily in the areas of mergers and acquisitions, financings and corporate strategy. Prior to that, Mr. O'Neil formed a law partnership with Paul Mishkin under the name Mishkin, O'Neil for the purpose of engaging in general corporate and business law. Prior to that, he co-founded two corporations, Syntro Corporation and NovaCare, Inc., which became public companies. Mr. O'Neil commenced his legal career at Cravath Swaine & Moore. Mr. O'Neil has also held a series of executive positions at City Investing Company, including President and Vice Chairman. - Stephen E. O'Neil自2005年7月起担任Alphatec Holdings，Inc.和Alphatecs Spine的董事。1991年5月，他成立了O'Neil Group，主要在并购、融资和公司战略领域向客户提供法律和财务咨询。在此之前，O'Neil先生与保罗·米什金（Paul Mishkin）以米什金·奥尼尔的名义建立了法律合伙关系，以从事一般公司法和商业法。在此之前，他共同创立了两家公司，Syntro Corporation和NovaCare，Inc.，这两家公司后来成为上市公司。O'Neil先生在Cravath Swaine&Moore开始了他的法律生涯。O'Neil先生还曾在City Investing Company担任过一系列高管职位，包括总裁和副董事长。
- Stephen E. O'Neil has served as a Director of Alphatec Holdings, Inc. and Alphatec Spine since July 2005. In May 1991 he founded The O'Neil Group, which provided legal and financial advice to clients primarily in the areas of mergers and acquisitions, financings and corporate strategy. Prior to that, Mr. O'Neil formed a law partnership with Paul Mishkin under the name Mishkin, O'Neil for the purpose of engaging in general corporate and business law. Prior to that, he co-founded two corporations, Syntro Corporation and NovaCare, Inc., which became public companies. Mr. O'Neil commenced his legal career at Cravath Swaine & Moore. Mr. O'Neil has also held a series of executive positions at City Investing Company, including President and Vice Chairman.
- David H. Mowry
-
David H. Mowry，2013年2月至今，担任本公司的总裁、首席执行官；2013年6月至今，担任执行董事。他于2011年7月加入本公司，担任首席运营官；2012年11月，他被任命为临时总裁、首席执行官；2013年2月，正式担任总裁、首席执行官。他有着超过24年的医疗器械行业的经验。加入本公司之前，2010年7月至2011年7月，他担任Covidien plc的全球神经血管部门总裁，这是一个国际性的医疗产品供应商。2010年1月至2010年7月，他担任ev3 Inc的高级副总裁、全球心血管总裁，这是一个全球性的血管内置产品供应商，在2010年7月被Covidien收购。2007年8月至2010年1月，他是ev3的全球运营高级副总裁。此前，2006年11月至2007年10月，他担任ev3心血管理运营副总裁。加入ev3之前，2002年2月至2006年11月，他在 Zimmer Holdings的Zimmer Spine分部担任运营与物流副总裁，这是一个重建与脊柱植入物、外伤及相关整形外科产品的公司。加入Zimmer之前，他是医疗器械公司HeartStent Corp的总裁、首席运营官。他毕业于纽约的United States Military Academy in West Point，获得工程与数学学位。
David H. Mowry was appointed as the Company's Chief Executive Officer and a member of the Board on July 8 2019. Prior to joining Cutera, from May 2016 to October 2018 Mr. Mowry served as President and Chief Executive Officer, as well as a member of the Board of Directors, of Vyaire Medical, a global leader in the respiratory diagnostics, ventilation, and anesthesia delivery and patient monitoring market segments. Prior to his assignment at Vyaire, Mr. Mowry served as Executive Vice President and Chief Operating Officer and member of the Board of Directors of Wright Medical Group N.V., a global medical device company focused on extremities and biologics products, from October 2015 to May 2016 and during this time period he was also a member of the Board of Directors of EndoChoice Holdings, Inc., a company focused on the manufacturing and commercialization of platform technologies relating to the treatment of gastrointestinal conditions. Prior to Mr. Mowry's assignment at Wright Medical Group, he served as President and Chief Executive Officer and member of the Board of Directors of Tornier N.V. from February 2013 until October 2015 at which time Tornier and Wright Medical Group merged, and prior to that, as Chief Operating Officer of Tornier from 2011 to 2013. Within the spine industry, Mr. Mowry served as Vice President of Operations and Logistics at Zimmer Spine from February 2002 until October 2006. Mr. Mowry has held executive leadership positions over his thirty year medical device career at Covidien plc, ev3 Inc. and Zimmer Spine, Inc. Mr. Mowry is on the Board of directors of Alphatec Holdings, Inc., a public medical technology company that designs, develops, and markets products for the surgical treatment of spine disorders. Mr. Mowry received a B.S. degree in Engineering from the United States Military Academy at West Point. - David H. Mowry，2013年2月至今，担任本公司的总裁、首席执行官；2013年6月至今，担任执行董事。他于2011年7月加入本公司，担任首席运营官；2012年11月，他被任命为临时总裁、首席执行官；2013年2月，正式担任总裁、首席执行官。他有着超过24年的医疗器械行业的经验。加入本公司之前，2010年7月至2011年7月，他担任Covidien plc的全球神经血管部门总裁，这是一个国际性的医疗产品供应商。2010年1月至2010年7月，他担任ev3 Inc的高级副总裁、全球心血管总裁，这是一个全球性的血管内置产品供应商，在2010年7月被Covidien收购。2007年8月至2010年1月，他是ev3的全球运营高级副总裁。此前，2006年11月至2007年10月，他担任ev3心血管理运营副总裁。加入ev3之前，2002年2月至2006年11月，他在 Zimmer Holdings的Zimmer Spine分部担任运营与物流副总裁，这是一个重建与脊柱植入物、外伤及相关整形外科产品的公司。加入Zimmer之前，他是医疗器械公司HeartStent Corp的总裁、首席运营官。他毕业于纽约的United States Military Academy in West Point，获得工程与数学学位。
- David H. Mowry was appointed as the Company's Chief Executive Officer and a member of the Board on July 8 2019. Prior to joining Cutera, from May 2016 to October 2018 Mr. Mowry served as President and Chief Executive Officer, as well as a member of the Board of Directors, of Vyaire Medical, a global leader in the respiratory diagnostics, ventilation, and anesthesia delivery and patient monitoring market segments. Prior to his assignment at Vyaire, Mr. Mowry served as Executive Vice President and Chief Operating Officer and member of the Board of Directors of Wright Medical Group N.V., a global medical device company focused on extremities and biologics products, from October 2015 to May 2016 and during this time period he was also a member of the Board of Directors of EndoChoice Holdings, Inc., a company focused on the manufacturing and commercialization of platform technologies relating to the treatment of gastrointestinal conditions. Prior to Mr. Mowry's assignment at Wright Medical Group, he served as President and Chief Executive Officer and member of the Board of Directors of Tornier N.V. from February 2013 until October 2015 at which time Tornier and Wright Medical Group merged, and prior to that, as Chief Operating Officer of Tornier from 2011 to 2013. Within the spine industry, Mr. Mowry served as Vice President of Operations and Logistics at Zimmer Spine from February 2002 until October 2006. Mr. Mowry has held executive leadership positions over his thirty year medical device career at Covidien plc, ev3 Inc. and Zimmer Spine, Inc. Mr. Mowry is on the Board of directors of Alphatec Holdings, Inc., a public medical technology company that designs, develops, and markets products for the surgical treatment of spine disorders. Mr. Mowry received a B.S. degree in Engineering from the United States Military Academy at West Point.
- Terry M. Rich
-
Terry M. Rich，2012年3月至今，担任本公司的美国商业运营高级副总裁。加入本公司之前，他是NuVasive的西部销售高级副总裁，这是一个医疗器械公司，专注于为脊椎微创手术开发产品和流程。担任该职之前，2005年12月以来，他在NuVasive担任过区域副总裁、销售总监、区域业务经理。加入NuVasive之前，2004年7月至2005年12月，他在DePuy Spine, Inc担任湾区脊椎业务的合伙人/区域销售经理，这是一个脊椎业务公司，也是Johnson & Johnson的子公司。他在Rutgers College, Rutgers University获得劳工关系学士学位。
Terry M. Rich has served as a Director and Chief Executive Officer of us and Alphatec Spine since December 2016.Prior to joining us, from October 2015 to June 2016 Mr. Rich was the President, Upper Extremities of Wright Medical Group, N.V., a global medical device company focused on extremities and biologics products. Prior to that, Mr. Rich served as Senior Vice President of U.S. Commercial Operations of Tornier, N.V., from March 2012 to October 2015 at which time Tornier and Wright Medical Group merged. Prior to joining Tornier, Mr. Rich held increasingly senior sales leadership positions at NuVasive, Inc., a San Diego-based spinal implant medical device company, from December 2005 until leaving the company in March 2012 as Senior Vice President, Sales, West. Prior to joining NuVasive, Mr. Rich served as Partner/Area Sales Manager of Bay Area Spine, a distributor of DePuy Spine, Inc.’s products. Mr. Rich earned a B.S. degree in Labor and Industrial Relations from Rutgers University. - Terry M. Rich，2012年3月至今，担任本公司的美国商业运营高级副总裁。加入本公司之前，他是NuVasive的西部销售高级副总裁，这是一个医疗器械公司，专注于为脊椎微创手术开发产品和流程。担任该职之前，2005年12月以来，他在NuVasive担任过区域副总裁、销售总监、区域业务经理。加入NuVasive之前，2004年7月至2005年12月，他在DePuy Spine, Inc担任湾区脊椎业务的合伙人/区域销售经理，这是一个脊椎业务公司，也是Johnson & Johnson的子公司。他在Rutgers College, Rutgers University获得劳工关系学士学位。
- Terry M. Rich has served as a Director and Chief Executive Officer of us and Alphatec Spine since December 2016.Prior to joining us, from October 2015 to June 2016 Mr. Rich was the President, Upper Extremities of Wright Medical Group, N.V., a global medical device company focused on extremities and biologics products. Prior to that, Mr. Rich served as Senior Vice President of U.S. Commercial Operations of Tornier, N.V., from March 2012 to October 2015 at which time Tornier and Wright Medical Group merged. Prior to joining Tornier, Mr. Rich held increasingly senior sales leadership positions at NuVasive, Inc., a San Diego-based spinal implant medical device company, from December 2005 until leaving the company in March 2012 as Senior Vice President, Sales, West. Prior to joining NuVasive, Mr. Rich served as Partner/Area Sales Manager of Bay Area Spine, a distributor of DePuy Spine, Inc.’s products. Mr. Rich earned a B.S. degree in Labor and Industrial Relations from Rutgers University.
高管简历
中英对照 | 中文 | 英文- Jonathan Allen
Jonathan Allen自2016年12月起担任美国和Alphatec Spine的执行Vice President。在他27年的医疗器械职业生涯中，Allen先生在脊柱和骨科担任过许多销售领导和运营职位。在加入我们之前，从2012年8月到2016年9月，他在Wright Medical Group担任Vice President，梦百合经济学和报销，并在Tornier N.V.被Wright Medical收购之前担任Vice President，负责销售业务。从1990年到2011年，他曾担任DePuy Spine Organization的高级领导职务，在那里他曾开发定价和商业策略，并拥有一个多州分销机构。
Jonathan Allen has served as Executive Vice President, Commercial Operations of us and Alphatec Spine since December 2016. Mr. Allen has held numerous sales leadership and operations positions in spine and orthopedics over his 27-year career in medical devices. Before joining us, from August 2012 until September 2016 he was Vice President, Healthcare Economics and Reimbursement at Wright Medical Group, and Vice President, Sales Operations with Tornier N.V., prior to its acquisition by Wright Medical. From 1990 to 2011 Mr. Allen held senior leadership roles within the DePuy Spine organization, where he developed pricing and commercial strategy, and owned a multi-state distributorship.- Jonathan Allen自2016年12月起担任美国和Alphatec Spine的执行Vice President。在他27年的医疗器械职业生涯中，Allen先生在脊柱和骨科担任过许多销售领导和运营职位。在加入我们之前，从2012年8月到2016年9月，他在Wright Medical Group担任Vice President，梦百合经济学和报销，并在Tornier N.V.被Wright Medical收购之前担任Vice President，负责销售业务。从1990年到2011年，他曾担任DePuy Spine Organization的高级领导职务，在那里他曾开发定价和商业策略，并拥有一个多州分销机构。
- Jonathan Allen has served as Executive Vice President, Commercial Operations of us and Alphatec Spine since December 2016. Mr. Allen has held numerous sales leadership and operations positions in spine and orthopedics over his 27-year career in medical devices. Before joining us, from August 2012 until September 2016 he was Vice President, Healthcare Economics and Reimbursement at Wright Medical Group, and Vice President, Sales Operations with Tornier N.V., prior to its acquisition by Wright Medical. From 1990 to 2011 Mr. Allen held senior leadership roles within the DePuy Spine organization, where he developed pricing and commercial strategy, and owned a multi-state distributorship.
- Brian R. Snider
BrianR.Snider自2017年3月起担任美国和Alphatec Spine的执行Vice President，战略营销和产品开发。在加入我们之前，从2008年2月到2017年3月，Snider先生在Nuvasive，Inc.担任过各种营销领导和全球产品管理职务最近，从2014年9月至2017年3月，他担任Sr。胸腰椎前路的董事兼业务主管，包括全面负责脊柱前路业务，包括XLIF®；，Nuvasive，Inc.’；的横向手术程序。Snider从2006年6月到2008年2月在Alveolus，Inc.（一家设备公司，专注于介入支架技术）担任营销领导职位。他也曾任职KPMG Consulting公司（从2001年6月到2006年6月），任职于多种业务部门，包括生命科学。Snider先生在杜克大学（Duke University）福夸商学院（Fuqua School of Business）获得工商管理硕士学位，并在乔治华盛顿大学（George Washington University）获得营销与信息系统学士学位。
Brian R. Snider has served as Executive Vice President, Strategic Marketing and Product Development of us and Alphatec Spine since March 2017. Prior to joining us, from February 2008 until March 2017 Mr. Snider held various marketing leadership and global product management roles within NuVasive, Inc. Most recently, from September 2014 to March 2017 he served as Sr. Director and Business Lead of Thoracolumbar Anterior, which included overall responsibility for the anterior spinal column business, including XLIF®, NuVasive, Inc.’s lateral surgery procedure. From June 2006 to February 2008 Mr. Snider held marketing leadership roles with Alveolus, Inc., a device company focused on interventional stent technologies. He also worked, from June 2001 to June 2006 at KPMG Consulting, in various business units, including Life Sciences. Mr. Snider received an M.B.A. degree from the Fuqua School of Business at Duke University and a B.A. degree in Marketing and Information Systems from George Washington University.- BrianR.Snider自2017年3月起担任美国和Alphatec Spine的执行Vice President，战略营销和产品开发。在加入我们之前，从2008年2月到2017年3月，Snider先生在Nuvasive，Inc.担任过各种营销领导和全球产品管理职务最近，从2014年9月至2017年3月，他担任Sr。胸腰椎前路的董事兼业务主管，包括全面负责脊柱前路业务，包括XLIF®；，Nuvasive，Inc.’；的横向手术程序。Snider从2006年6月到2008年2月在Alveolus，Inc.（一家设备公司，专注于介入支架技术）担任营销领导职位。他也曾任职KPMG Consulting公司（从2001年6月到2006年6月），任职于多种业务部门，包括生命科学。Snider先生在杜克大学（Duke University）福夸商学院（Fuqua School of Business）获得工商管理硕士学位，并在乔治华盛顿大学（George Washington University）获得营销与信息系统学士学位。
- Brian R. Snider has served as Executive Vice President, Strategic Marketing and Product Development of us and Alphatec Spine since March 2017. Prior to joining us, from February 2008 until March 2017 Mr. Snider held various marketing leadership and global product management roles within NuVasive, Inc. Most recently, from September 2014 to March 2017 he served as Sr. Director and Business Lead of Thoracolumbar Anterior, which included overall responsibility for the anterior spinal column business, including XLIF®, NuVasive, Inc.’s lateral surgery procedure. From June 2006 to February 2008 Mr. Snider held marketing leadership roles with Alveolus, Inc., a device company focused on interventional stent technologies. He also worked, from June 2001 to June 2006 at KPMG Consulting, in various business units, including Life Sciences. Mr. Snider received an M.B.A. degree from the Fuqua School of Business at Duke University and a B.A. degree in Marketing and Information Systems from George Washington University.
- Jeffrey G. Black
Jeffrey G. Black，2014年4月起担任我们的财务总监。2011年3月一直到2013年12月该公司被BASF Corporation收购前，在一家生命科学公司-Verenium Corporation担任财务总监；2005年4月-2011年3月担任Verenium Corporation首席会计官。2003年9月-2005年4月，他在Isis Pharmaceuticals, Inc. 担任会计执行总监和总会计师。2000年9月-2003年8月，他在一家财务顾问公司-Regent Pacific Management Corporation担任负责人和临时财务执行；曾担任 Clarent Corporation的财务副总裁和企业总会计师；以及曾在Accelerated Networks, Inc.担任副总裁和企业总会计师，这两家都是电信科技公司。他是一名注册会计师（非执业），在Ernst & Young LLP开始他的职业生涯。他目前在一家私有生物科技公司-Cellana, Inc.董事会任职。他持有Arizona大学的商务学士学位。
Jeffrey G. Black has served as Executive Vice President and Chief Financial Officer of us and Alphatec Spine since March 2017. Prior to joining us, from September 2015 until March 2017 Mr. Black was Chief Financial Officer of Applied Proteomics, Inc., a privately-held, non-invasive, proteomics-based diagnostics company. From April 2014 until September 2015 Mr. Black was Chief Financial Officer of AltheaDx, Inc., a privately-held pharmacogenetics diagnostics company. Before joining AltheaDx, Mr. Black was employed by Verenium Corporation formerly Diversa Corporation, a clean technology company, where he served as Chief Accounting Officer from April 2005 until February 2011 and Chief Financial Officer from February 2011 through December 2013. He also served as Executive Director of Accounting and Corporate Controller of Ionis Pharmaceuticals (formerly ISIS Pharmaceuticals), a drug discovery company, as well as in finance and controller roles at Lightspan, Inc., TriTeal Corporation and Chiron Mimotopes Peptide Systems, LLC. He is a Certified Public Accountant (inactive), and is a member of the Board of Directors of Cellana, Inc., a San Diego-based algae bioproducts company. Mr. Black received a B.S. degree in Business from the University of Arizona.- Jeffrey G. Black，2014年4月起担任我们的财务总监。2011年3月一直到2013年12月该公司被BASF Corporation收购前，在一家生命科学公司-Verenium Corporation担任财务总监；2005年4月-2011年3月担任Verenium Corporation首席会计官。2003年9月-2005年4月，他在Isis Pharmaceuticals, Inc. 担任会计执行总监和总会计师。2000年9月-2003年8月，他在一家财务顾问公司-Regent Pacific Management Corporation担任负责人和临时财务执行；曾担任 Clarent Corporation的财务副总裁和企业总会计师；以及曾在Accelerated Networks, Inc.担任副总裁和企业总会计师，这两家都是电信科技公司。他是一名注册会计师（非执业），在Ernst & Young LLP开始他的职业生涯。他目前在一家私有生物科技公司-Cellana, Inc.董事会任职。他持有Arizona大学的商务学士学位。
- Jeffrey G. Black has served as Executive Vice President and Chief Financial Officer of us and Alphatec Spine since March 2017. Prior to joining us, from September 2015 until March 2017 Mr. Black was Chief Financial Officer of Applied Proteomics, Inc., a privately-held, non-invasive, proteomics-based diagnostics company. From April 2014 until September 2015 Mr. Black was Chief Financial Officer of AltheaDx, Inc., a privately-held pharmacogenetics diagnostics company. Before joining AltheaDx, Mr. Black was employed by Verenium Corporation formerly Diversa Corporation, a clean technology company, where he served as Chief Accounting Officer from April 2005 until February 2011 and Chief Financial Officer from February 2011 through December 2013. He also served as Executive Director of Accounting and Corporate Controller of Ionis Pharmaceuticals (formerly ISIS Pharmaceuticals), a drug discovery company, as well as in finance and controller roles at Lightspan, Inc., TriTeal Corporation and Chiron Mimotopes Peptide Systems, LLC. He is a Certified Public Accountant (inactive), and is a member of the Board of Directors of Cellana, Inc., a San Diego-based algae bioproducts company. Mr. Black received a B.S. degree in Business from the University of Arizona.
- Craig E. Hunsaker
Craig E. Hunsaker从2011年1月开始担任我司全球人力资源部的高级副总裁。从2010年1月到2010年12月，Hunsaker先生开始担任我司人力资源部副总裁，从2009年8月到2009年12月，Hunsaker先生开始担任我司法律事务部副总裁。从2006年6月到2009年7月，Hunsaker先生担任Mintz, Levin, Ferris, Glovsky & Popeo P.C。的圣地亚哥办事处的经营合伙人，他在那里负责圣地亚哥办事处运营的各个方面。从2003年1月到2006年6月，Hunsaker先生担任Fish & Richardson P.C。圣地亚哥办事处的负责人，他在那里的最后2年担任该公司加利福尼亚州聘雇实习部负责人。Hunsaker先生先前的工作经历还包括以下方面：担任Brobeck Phleger & Harrison LLP的高级合伙人，担任Cooley Godward LLP的诉讼合伙人，担任 Morgan Lewis and Bockius LLP的劳动合伙人。Hunsaker先生在杨百翰大学获得国际商务与财务学理学学士学位，并在哥伦比亚大学法学院获得法学博士学位。
Craig E. Hunsaker joined us and Alphatec Spine in September 2016 as Executive Vice President, People & Culture, and added the roles of General Counsel and Corporate Secretary on March 1 2017. Prior to joining us, from April 2014 until September 2016 Mr. Hunsaker was a consultant in the areas of human resources and employment law including, from April 2014 to September 2014 Senior Advisor, Human Resources, for General Atomics, a San Diego-based defense contractor. Prior to that, from August 2009 until March 2014 he served as Senior Vice President, Global Human Resources and Vice President, Legal Affairs at NuVasive, Inc. Before joining NuVasive, Mr. Hunsaker was a practicing lawyer, specializing in trade secret protection and employment law. He was a partner in, and Managing Member of, the San Diego offices of law firms Mintz, Levin, Cohn, Ferris Glovsky and Popeo, P.C., and Fish & Richardson, P.C., and an associate in the San Diego offices of law firms Brobeck, Phleger & Harrison, LLP and Cooley LLP, and the Los Angeles office of Morgan, Lewis and Bockius. LLP. He received his Juris Doctorate from Columbia University School of Law, and a B.S. degree in Finance and International Business from Brigham Young University. He is admitted to practice law in all state and federal courts in the State of California.- Craig E. Hunsaker从2011年1月开始担任我司全球人力资源部的高级副总裁。从2010年1月到2010年12月，Hunsaker先生开始担任我司人力资源部副总裁，从2009年8月到2009年12月，Hunsaker先生开始担任我司法律事务部副总裁。从2006年6月到2009年7月，Hunsaker先生担任Mintz, Levin, Ferris, Glovsky & Popeo P.C。的圣地亚哥办事处的经营合伙人，他在那里负责圣地亚哥办事处运营的各个方面。从2003年1月到2006年6月，Hunsaker先生担任Fish & Richardson P.C。圣地亚哥办事处的负责人，他在那里的最后2年担任该公司加利福尼亚州聘雇实习部负责人。Hunsaker先生先前的工作经历还包括以下方面：担任Brobeck Phleger & Harrison LLP的高级合伙人，担任Cooley Godward LLP的诉讼合伙人，担任 Morgan Lewis and Bockius LLP的劳动合伙人。Hunsaker先生在杨百翰大学获得国际商务与财务学理学学士学位，并在哥伦比亚大学法学院获得法学博士学位。
- Craig E. Hunsaker joined us and Alphatec Spine in September 2016 as Executive Vice President, People & Culture, and added the roles of General Counsel and Corporate Secretary on March 1 2017. Prior to joining us, from April 2014 until September 2016 Mr. Hunsaker was a consultant in the areas of human resources and employment law including, from April 2014 to September 2014 Senior Advisor, Human Resources, for General Atomics, a San Diego-based defense contractor. Prior to that, from August 2009 until March 2014 he served as Senior Vice President, Global Human Resources and Vice President, Legal Affairs at NuVasive, Inc. Before joining NuVasive, Mr. Hunsaker was a practicing lawyer, specializing in trade secret protection and employment law. He was a partner in, and Managing Member of, the San Diego offices of law firms Mintz, Levin, Cohn, Ferris Glovsky and Popeo, P.C., and Fish & Richardson, P.C., and an associate in the San Diego offices of law firms Brobeck, Phleger & Harrison, LLP and Cooley LLP, and the Los Angeles office of Morgan, Lewis and Bockius. LLP. He received his Juris Doctorate from Columbia University School of Law, and a B.S. degree in Finance and International Business from Brigham Young University. He is admitted to practice law in all state and federal courts in the State of California.
- Terry M. Rich
Terry M. Rich，2012年3月至今，担任本公司的美国商业运营高级副总裁。加入本公司之前，他是NuVasive的西部销售高级副总裁，这是一个医疗器械公司，专注于为脊椎微创手术开发产品和流程。担任该职之前，2005年12月以来，他在NuVasive担任过区域副总裁、销售总监、区域业务经理。加入NuVasive之前，2004年7月至2005年12月，他在DePuy Spine, Inc担任湾区脊椎业务的合伙人/区域销售经理，这是一个脊椎业务公司，也是Johnson & Johnson的子公司。他在Rutgers College, Rutgers University获得劳工关系学士学位。
Terry M. Rich has served as a Director and Chief Executive Officer of us and Alphatec Spine since December 2016.Prior to joining us, from October 2015 to June 2016 Mr. Rich was the President, Upper Extremities of Wright Medical Group, N.V., a global medical device company focused on extremities and biologics products. Prior to that, Mr. Rich served as Senior Vice President of U.S. Commercial Operations of Tornier, N.V., from March 2012 to October 2015 at which time Tornier and Wright Medical Group merged. Prior to joining Tornier, Mr. Rich held increasingly senior sales leadership positions at NuVasive, Inc., a San Diego-based spinal implant medical device company, from December 2005 until leaving the company in March 2012 as Senior Vice President, Sales, West. Prior to joining NuVasive, Mr. Rich served as Partner/Area Sales Manager of Bay Area Spine, a distributor of DePuy Spine, Inc.’s products. Mr. Rich earned a B.S. degree in Labor and Industrial Relations from Rutgers University.- Terry M. Rich，2012年3月至今，担任本公司的美国商业运营高级副总裁。加入本公司之前，他是NuVasive的西部销售高级副总裁，这是一个医疗器械公司，专注于为脊椎微创手术开发产品和流程。担任该职之前，2005年12月以来，他在NuVasive担任过区域副总裁、销售总监、区域业务经理。加入NuVasive之前，2004年7月至2005年12月，他在DePuy Spine, Inc担任湾区脊椎业务的合伙人/区域销售经理，这是一个脊椎业务公司，也是Johnson & Johnson的子公司。他在Rutgers College, Rutgers University获得劳工关系学士学位。
- Terry M. Rich has served as a Director and Chief Executive Officer of us and Alphatec Spine since December 2016.Prior to joining us, from October 2015 to June 2016 Mr. Rich was the President, Upper Extremities of Wright Medical Group, N.V., a global medical device company focused on extremities and biologics products. Prior to that, Mr. Rich served as Senior Vice President of U.S. Commercial Operations of Tornier, N.V., from March 2012 to October 2015 at which time Tornier and Wright Medical Group merged. Prior to joining Tornier, Mr. Rich held increasingly senior sales leadership positions at NuVasive, Inc., a San Diego-based spinal implant medical device company, from December 2005 until leaving the company in March 2012 as Senior Vice President, Sales, West. Prior to joining NuVasive, Mr. Rich served as Partner/Area Sales Manager of Bay Area Spine, a distributor of DePuy Spine, Inc.’s products. Mr. Rich earned a B.S. degree in Labor and Industrial Relations from Rutgers University.
- Michael Plunkett
Michael Plunkett 自2012年3月开始加入Alphatec Spine公司，担任运营副总监，并在2014年1月提升为运营总监。他在运营，信息技术以及程序管理分别任职过多个岗位。在加入该公司前，他曾在2003年8月至2012年3月期间在 First Marblehead 公司担任高层职位。他最后的岗位是总经理。在加入First Marblehead公司前，他曾在美国海军参军24年，并在2003年7约退休，当时他的头衔是首长。在参加海军期间，他在陆上和海上都担任过各种职位，其中包括美国约翰·C·斯坦尼斯号航母的供应链主任，海军作战，戒备以及物流部副主任。
Michael Plunkett joined us and Alphatec Spine in March 2012 as Vice President of Operations, was promoted to Chief Operating Officer in January 2014 and became President and Chief Operating Officer in September 2016. Prior to joining us, Mr. Plunkett had increasing positions of responsibility and authority from August 2003 to March 2012 at First Marblehead Corporation “First Marblehead”, a provider of private student loan solutions. When he left First Marblehead in 2012 he was its Managing Director. Prior to joining First Marblehead, Mr. Plunkett served over 24 years in the U.S. Navy and retired with the rank of Captain in July 2003. While in the Navy, he served in a variety of ashore and afloat positions, including Supply Officer, USS John C. Stennis (CVN 74) and the primary assistant to the Deputy Chief of Naval Operations, Fleet Readiness and Logistics. Mr. Plunkett earned a B.S. degree in Accounting from Saint John Fisher College, an M.S. degree in Financial Management from Naval Postgraduate School, and an M.A. degree in Strategic Studies, International Relations from the Naval War College.- Michael Plunkett 自2012年3月开始加入Alphatec Spine公司，担任运营副总监，并在2014年1月提升为运营总监。他在运营，信息技术以及程序管理分别任职过多个岗位。在加入该公司前，他曾在2003年8月至2012年3月期间在 First Marblehead 公司担任高层职位。他最后的岗位是总经理。在加入First Marblehead公司前，他曾在美国海军参军24年，并在2003年7约退休，当时他的头衔是首长。在参加海军期间，他在陆上和海上都担任过各种职位，其中包括美国约翰·C·斯坦尼斯号航母的供应链主任，海军作战，戒备以及物流部副主任。
- Michael Plunkett joined us and Alphatec Spine in March 2012 as Vice President of Operations, was promoted to Chief Operating Officer in January 2014 and became President and Chief Operating Officer in September 2016. Prior to joining us, Mr. Plunkett had increasing positions of responsibility and authority from August 2003 to March 2012 at First Marblehead Corporation “First Marblehead”, a provider of private student loan solutions. When he left First Marblehead in 2012 he was its Managing Director. Prior to joining First Marblehead, Mr. Plunkett served over 24 years in the U.S. Navy and retired with the rank of Captain in July 2003. While in the Navy, he served in a variety of ashore and afloat positions, including Supply Officer, USS John C. Stennis (CVN 74) and the primary assistant to the Deputy Chief of Naval Operations, Fleet Readiness and Logistics. Mr. Plunkett earned a B.S. degree in Accounting from Saint John Fisher College, an M.S. degree in Financial Management from Naval Postgraduate School, and an M.A. degree in Strategic Studies, International Relations from the Naval War College.